The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
The user is considering adding 2% ketoconazole to their current treatment of oral minoxidil and finasteride to address scalp itchiness and inflammation. Another user suggests controlling inflammation is important for managing hair loss.
RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.
Finasteride is believed to slow down hair loss significantly, but may not completely stop it for everyone. Effectiveness and duration vary by individual, with some users experiencing positive results for over 10 years, while others see less benefit.
The conversation discusses the use of Procapil 5% for hair loss. Users inquire about its effectiveness and share experiences with treatments like Minoxidil, Finasteride, and RU58841.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
Hair loss discussion mentions Minoxidil, finasteride, and RU58841 treatments. Regenepure shampoo's ketoconazole ingredient causes confusion due to inconsistent listings.
The conversation discusses using Latanoprost for hair regrowth, with the original poster seeking advice on where to purchase it without a prescription. Users suggest alternatives like Triple Hair's TH-07, which includes Finasteride, Minoxidil, and Latanoprost, and Strut's Latanoprost with melatonin and caffeine.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.